Autologous versus allogeneic versus umbilical cord sera for the treatment of severe dry eye disease: a double-blind randomized clinical trial.
Sjögren’s syndrome
allogeneic serum eye drops
autoimmune disease
autologous serum eye drops
dry eye
growth factor
haemoderivatives eye drops
ocular surface
umbilical cord serum eye drops
Journal
Acta ophthalmologica
ISSN: 1755-3768
Titre abrégé: Acta Ophthalmol
Pays: England
ID NLM: 101468102
Informations de publication
Date de publication:
Mar 2022
Mar 2022
Historique:
received:
08
01
2021
accepted:
31
05
2021
pubmed:
18
6
2021
medline:
1
3
2022
entrez:
17
6
2021
Statut:
ppublish
Résumé
To measure the effects of Autologous serum (AS), Allogeneic Serum (HS) and Umbilical Cord serum (CS) eye drops in severe dry eye disease (DES), as well as to characterize and quantify several molecules in the three sera (albumin, fibronectin; Vitamin A and E; IgG, IgA and IgM; Transforming growth factor β; Epithelial growth factor). Randomized, double-blind, single-centre, three-arm (AS, HS and CS) clinical trial. Sixty-three subjects were included with severe DES, 21 in each arm of the study. Visual acuity, Schirmer test, Breakup time (BUT), lissamine green, fluorescein staining measurements and a questionnaire were performed prior to treatment, and after one-month and three-month follow-up. There was a significant main effect of time on visual acuities, Schirmer and BUT tests and fluorescein and lissamine green staining measurements and questionnaire scores (p = 0.015, p = 0.002, p < 0.001, p < 0.001, p = 0.031 and p < 0.001, respectively), although there was no significant interaction between time and serum type, nor between serum type and the test performed. Regarding the concentration of molecules, in our study AS contained significantly higher concentrations of IgA, IgG and fibronectin whereas HS contained significantly higher concentration of IgM, vitamins A and E, TGF and albumin. Contrary to previous reports, CS did not show higher concentration of any of the molecules analysed. The three sera were effective in the treatment of severe DES. CS did not contain a higher proportion of molecules compared to AS/HS. More research is needed to assess the effect of AS in patients with DES and autoimmune diseases.
Substances chimiques
Ophthalmic Solutions
0
Types de publication
Journal Article
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
e396-e408Subventions
Organisme : Ministry of Health within the framework of the Aid for Independent Clinical Research of 2011
ID : EC11-506
Informations de copyright
© 2021 Acta Ophthalmologica Scandinavica Foundation. Published by John Wiley & Sons Ltd.
Références
Ali TK, Gibbons A, Cartes C et al. (2018): Use of autologous serum tears for the treatment of ocular surface disease from patients with systemic autoimmune diseases. Am J Ophthalmol 189: 65-70.
Baturone R, Soto Mj, Márquez M (2009): Health-related quality of life in patients with primary sjögren’s syndrome: relationship with serum levels of proinflammatory cytokines. Scand J Rheumatol 38: 386-389.
Benítez del Castillo JM (2002): Treatment of recurrent corneal erosions using autologous serum. Cornea 21: 781-878.
Borrelli M, Schröder C, Dart JK et al. (2010): Long-term follow-up after submandibular gland transplantation in severe dry eyes secondary to cicatrizing conjunctivitis. Am J Ophthalmol 150: 894.
Bosch-Valero J, Martín-Aviá J, Sierra-Barreras J, Rodríguez-Marco A & Cristóbal-Bescós Ja (2008): Suero autólogo en patología ocular por hipovitaminosis. Arch Soc Esp Oftalmol. 83: 45-48.
Bron JA, Victoria E & Janine A (2003): Grading of corneal and conjunctival staining in the context of other dry eye tests. Cornea 22: 640-650.
Campos E, Versura P, Buzzi M et al. (2020): Blood derived treatment from two allogeneic sources for severe dry eye associated to keratopathy: a multicentre randomised cross over clinical trial. Br J Ophthalmol 104: 114.
Celebi AR, Ulusoy C & Mirza GE (2014): The efficacy of autologous serum eye drops for severe dry eye syndrome: a randomized double-blind crossover study. Graefes Arch Clin Exp Ophthalmol 252: 619.
Chiang CC, Lin JM, Chen WL & Tsai YY (2007): Allogeneic serum eye drops for the treatment of severe dry eye in patients with chronic graft-versus-host disease. Cornea 26: 861-863.
Coghill JM, Sarantopoulos S, Moran TP, Murphy WJ, Blazar BR & Serody JS (2011): Effector CD4+ T cells, the cytokines they generate, and GVHD: something old and something new. Blood 117: 3268-3273.
Donate J, Benítez del Castillo JM, Fernández C & García Sánchez J (2002): Validación cuestionario para diagnóstico ojo seco. Arch Soc Esp Oftalmol 77: 493-550.
Douglas CM (2001): Design and analysis of experiments, 5th edn. Hoboken, NJ: John Wiley & Sons.
Foulks GN (2003): Challenges and pitfalls in clinical trials of treatments for dry eye. The Ocular Surface 1: 20-30.
Fox RI, Chan R & Michelson JB (1984): Beneficial effect of artificial tears made with autologous serum in patients with keratoconjunctivitis sicca. Arthritis Rheum 27: 459-620461.
Freire V, Andollo N, Etxebarria J, Hernáez-Moya R, Durán JA & Morales M-C (2014): Corneal wound healing promoted by 3 blood derivatives: an in vitro and in vivo comparative study. Cornea 33: 614-620.
Gayton JL (2009): Etiology, prevalence, and treatment of dry eye disease. Clin Ophthalmol 3: 405-412.
Geerling G, Daniels Jt, Dart J, Cree Ia & Khaw Pt (2001): Toxicity of natural tear substitutes in a fully defined culture model of human corneal epithelial cells. Invest Ophthalmol Vis Sci 42: 948-956.
Geerling G, Maclennan S & Hartwig D (2004): Autologous Serum Eye Drops for Ocular Surface Disorders. Br J Ophthalmol 88: 1467-1477.
Giannaccare G, Carnevali A & Senni C (2020): Umbilical cord blood and serum for the treatment of ocular diseases: a comprehensive review. Ophthalmol Ther 9: 235-242.
Goto E, Shimmura S, Shimazaki J & Tsubota K (2001): Treatment of superior limbic keratoconjunctivitis by application of autologous serum. Cornea 20: 807-810.
Han S, Hyon J & Woo S (2011): Prevalence of dry eye disease in an elderly korean population. Arch Ophthalmol 129: 633-638.
Harloff S, Hartwig D & Kasper K (2008): Epitheliotrophic capacity of serum eye drops from healthy donors versus serum from immunosuppressed patients with rheumatoid arthritis. Klin Monbl Augenheilkd. 225: 200.
Harritshøj LH, Nielsen C, Ullum H, Hansen MB & Julian HO (2014): Ready-made allogeneic abo-specific serum eye drops: production from regular male blood donors, clinical routine, safety and efficacy. Acta Ophthalmol 92: 783-786.
Hwang J, Chung S-H, Jeon S, Kwok S-K, Park S-H & Kim M-S (2014): Comparison of clinical efficacies of autologous serum eye drops in patients with primary and secondary sjögren syndrome. Cornea 33: 663-667.
Hyon JY, Lee YJ & Yun PY (2007): Management of ocular surface inflammation in sjögren syndrome. Córnea 26: S113-S121.
International Dry Eye Workshop (DEWS) 2007: Report of the management and therapy subcommittee of the international dry eye workshop. Ocular Surface 5: 163-178.
Jones L, Downie LE, Korb D et al. (2017): TFOS DEWS II management and therapy report. Ocul Surf 15: 575-662.
Karakosta A, Vassilaki M, Plainis S, Elfadl NH, Tsilimbaris M & Moschandreas J (2012): Choice of analytic approach for eye-specific outcomes: one eye or two? Am J Ophthalmol 153: 571.
Kojima T, Ishida R, Dogru M, Goto E, Matsumoto Y, Kaido M & Tsubota K (2005): The effect of autologous serum eyedrops in the treatment of severe dry eye disease: a prospective randomized case-control study. Am J Ophthalmol 139: 242-246.
Liu L, Hartwig D, Harloff S, Herminghaus P, Wedel T & Geerling G (2005): An optimised protocol for the production of autologous serum eyedrops. Graefes Arch Clin Exp Ophthalmol 243: 706-711.
López-García JS, García-Lozano I, Rivas L, Giménez C, Acera A & Suárez-Cortés T (2016a): Effects of autologous serum eye drops on conjunctival expression of MUC5AC in patients with ocular surface disorders. Cornea 35: 336-341.
Lopez-García JS, García-Lozano I, Rivas L & Lopez-García JS (2016b): Stability of growth factors in autologous serum eyedrops after long-term storage. Curr Eye Res 41: 292. et al. Stability of Growth Factors in Autologous Serum Eyedrops after Long-Term Storage. Curr Eye Res 41: 292.
López-García Js, Rivas L, García-Lozano I & Murube J (2008): Autologous serum eyedrops in the treatment of aniridic keratopathy. Ophthalmology 115: 262-267.
Marks Dc & van der Meer Pf (2017): Biomedical Excellence for Safer Transfusion (BEST) Collaborative. Serum eye drops: a survey of international production methods. Vox Sang 112: 310.
Matsumoto Y (2004): Autologous serum application in the treatment of neurotrophic keratopathy. Ophthalmology 111: 115-122.
McDonnell PJ, Schanzlin DJ & Rao NA (1988): Immunoglobulin deposition in the cornea after application of autologous serum. Arch Ophthalmol 106: 14.
Miljanovic B, Dana R, Sullivan DA & Schaumberg DA (2007): Impact of dry eye syndrome on vision-related quality of life. Am J Ophthalmol 143: 409-411.
Murube J (2003): Surgical treatment of dry eye. Orbit 22: 203-232.
Na KS & Kim MS (2012): Allogeneic serum eye drops for the treatment of dry eye patients with chronic graft-versus-host disease. J Ocul Pharmacol Ther 28: 479-483.
Nelson JD & Gordon JF (1992): Topical fibronectin in the treatment of keratoconjunctivitis sicca. Chiron keratoconjunctivitis sicca study group. Am J Ophthalmol 114: 441-447.
Noble BA, Loh RS & MacLennan S (2004): Comparison of Autologous serum eye drops with conventional therapy in a randomised controlled crossover trial for ocular surface disease. Br J Ophthalmol 88: 647-652.
Ogawa Y (2003): Autologous serum eye drops for the treatment of severe dry eye in patients with chronic graft-versuhost disease. Bone Marrow Transplant 31: 579-583.
Pflugfelder SC (2008): Prevalence, burden, and pharmacoeconomics of dry eye disease. Am J Manag Care 14: S102-S106.
Poon AC, Geerling G & Dart JK (2001): Autologous serum eyedrops for dry eyes and epithelial defects: clinical and in vitro toxicity studies. Br J Ophthalmol 85: 1188-1189.
Qin J, Zhang L, Cai Z-G et al. (2013): Microvascular autologous transplantation of partial submandibular gland for severe keratoconjunctivitis sicca. Br J Ophthalmolhthalmol 97: 1123.
Sanchez-Avila RM, Merayo-Lloves J & Riestra AC (2017): The effect of immunologically safe plasma rich in growth factor eye drops in patients with sjogren syndrome. J Ocul Pharmacol Ther 33: 391.
Savini G, Prabhawasat P, Kojima T & Grueterich M (2008): The challenge of dry eye diagnosis. Clinical ophthalmology 2: 31-55.
Than J, Balal S, Wawrzynski J et al. (2017): Fingerprick autologous blood: a novel treatment for dry eye syndrome. Eye 31: 165.
Tsubota K (1999): Treatment of dry eye by autologous serum aplicattion in sjögren’s syndrome. Br J Ophthalmol 83: 390-439.
Tsubota K, Goto E, Shimmura S & Shimazaki J (1999): Treatment of persistent corneal epithelial defect by autologous serum application. Ophthalmolgy 106: 1984-.
Urzua CA, Vasquez DH, Huidobro A, Hernandez H & Alfaro J (2012): Randomized double-blind clinical trial of autologous serum versus artificial tears in dry eye syndrome. Curr Eye Res 37(8):684-.
van der Meer PF, Seghatchian J & de Korte D (2015): Autologous and allogeneic serum eye drops. The dutch perspective. Transfus Apher Sci 53: 99-101.
van der Meer PF, Seghatchian J & Marks DC (2016): Quality standards, safety and efficacy of blood-derived serum eye drops: a review. Transfus Apher Sci 54: 164-167.
Versura P, Buzzi M & Giannaccare G (2015): Targeting growth factor supply in keratopathy treatment: comparison between maternal peripheral blood and cord blood as sources for the preparation of topical eye drops. Blood Transfus 9: 1-7.
Versura P, Profazio V, Buzzi M, Stancari A, Arpinati M, Malavolta N & Campos EC (2013): Efficacy of standardized and quality-controlled cord blood serum eye drop therapy in the healing of severe corneal epithelial damage in dry eye. Cornea 32: 412-441.
Yılmaz U, Küçük E, Koç Ç & Gökler E (2017): Comparison of autologous serum versus preservative free artificial tear in patients with dry eyes due to systemic isotretinoin therapy. Curr Eye Res 42: 827-831.
Yoon KC (2014): Use of umbilical cord serum in ophthalmology. Chonnam Med J 50: 82-88.
Yoon K-C, Heo H, Im S-K, You I-C, Kim Y-H & Park Y-G (2007a): Comparison of autologous serum and umbilical cord serum eye drops for dry eye syndrome. Am J Ophthalmol 144: 86-92.
Yoon K-C, Im S-K, Park Y-G, Jung Y-D, Yang S-Y & Choi J (2006): Application of umbilical cord serum eyedrops for the treatment of dry eye syndrome. Cornea 25: 268-272.
Yoon K-c, Jeong I-y, Im S-k, Park Y-g, Kim H-j & Choi J (2007b): Therapeutic effect of umbilical cord serum eyedrops for the treatment of dry eye associated with graft-versus-host disease. Bone Marrow Transpl 39: 231-235.
Yoshino K, Garg R & Monroy D (1996): Production and secretion of transforming growth factor beta (TGF-Beta) by the human lacrimal gland. Curr Eye Res 15: 615-624.
Young Al, Cheng A, Ng Hk, Cheng Ll, Leung G & Lam D (2004): The use of autologous serum tears in persistent corneal epithelial defects. Eye 18: 609-661.
Yu G-y, Zhu Z-h, Mao C et al. (2004): Microvascular autologous submandibular gland transfer in severe cases of keratoconjunctivitis sicca. Int J Oral Maxillofac Surg 33: 235-239.